As part of its advocacy program in the United States, ACRO submits regulatory comments to US regulators. This comment letter, submitted by ACRO to FDA in 2022 about International Council for Harmonisation (ICH) Draft Guidance for Industry: Q9(R1) Quality Risk Management can be found below.